Liposomal drug delivery systems and anticancer drugs by Olusanya, Temidayo O. B. et al.
molecules
Review
Liposomal Drug Delivery Systems and
Anticancer Drugs
Temidayo O. B. Olusanya 1 ID , Rita Rushdi Haj Ahmad 1, Daniel M. Ibegbu 2, James R. Smith 3
and Amal Ali Elkordy 1,* ID
1 School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK;
Temidayo.olusanya@sunderland.ac.uk (T.O.B.O.); ritahajahmad@yahoo.co.uk (R.R.H.A.)
2 Department of Medical Biochemistry, College of Medicine, University of Nigeria Enugu Campus, Nigeria;
daniel.ibegbu@unn.edu.ng
3 School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK;
james.smith@port.ac.uk
* Correspondence: amal.elkordy@sunderland.ac.uk; Tel.: +44-(0)-191-515-2576; Fax: +44-(0)-191-515-3405
Received: 13 March 2018; Accepted: 9 April 2018; Published: 14 April 2018


Abstract: Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are
various causes of cancer, such as smoking, being overweight or obese, intake of processed meat,
radiation, family history, stress, environmental factors, and chance. The first-line treatment of
cancer is the surgical removal of solid tumours, radiation therapy, and chemotherapy. The systemic
administration of the free drug is considered to be the main clinical failure of chemotherapy in cancer
treatment, as limited drug concentration reaches the tumour site. Most of the active pharmaceutical
ingredients (APIs) used in chemotherapy are highly cytotoxic to both cancer and normal cells.
Accordingly, targeting the tumour vasculatures is essential for tumour treatment. In this context,
encapsulation of anti-cancer drugs within the liposomal system offers secure platforms for the
targeted delivery of anti-cancer drugs for the treatment of cancer. This, in turn, can be helpful for
reducing the cytotoxic side effects of anti-cancer drugs on normal cells. This short-review focuses on
the use of liposomes in anti-cancer drug delivery.
Keywords: liposomes; anticancer drugs; drug delivery
1. Introduction
There is a high demand for advanced delivery systems that are suitable for the delivery of various
active pharmaceutical ingredients (APIs), especially systems with low costs, high efficiency, low
risks, and toxicity [1]. Several APIs can be utilised better by employing nano-size drug delivery
systems (DDS) that are designed to enhance the delivery of APIs with poor pharmacokinetics
and biodistribution [2]. For instance, most of the chemotherapeutic medications are characterised
by poor pharmacokinetic profiles in addition to non-specific distribution in the body tissues and
organs, causing serious side effects and systemic toxicity [3]. Accordingly, nano-size structures-based
pharmaceutical formulations (e.g., liposomes [4], polymeric nanoparticles [5], electrosprayed
particles [6], and nanosuspension [7]) have demonstrated better therapy of the APIs. Moreover,
due to the complexity of solid tumours, an effective penetration of anti-cancer agents encapsulated
within a nanocarrier is the main challenge in cancer therapy [8]. Liposomes are the most commonly
investigated nanostructures used in advanced drug delivery, which were first discovered by Alee
Bangham in 1963 [9]. Liposomes are artificially spherical vesicles prepared from naturally-derived
phospholipid. They entail one or more lipid bilayers with discrete aqueous spaces. They are well
established for a range of pharmaceutical and biomedical applications with the unique capability
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of entrapment of both hydrophilic (polar) and hydrophobic (nonpolar) compounds due to their
amphipathic nature in aqueous media. For instance, hydrophobic compounds entrap in the bilayer
membrane, while hydrophilic compounds encapsulate in the aqueous core [10]. Liposomes serve
as DDSs due to their versatile structure; biocompatibility; and the fact they are naturally nontoxic,
non-immunogenic, and biodegradable [11]. Liposomes have several advantages contributing to drug
delivery. They have a role enhancing drug solubility [12], serving as a sustained release system [13],
providing targeted drug delivery [14], reducing the toxic effect of drugs [15], providing protection
against drug degradation [16], enhancing circulation half-life of APIs [17], being effective in overcoming
multidrug resistance [18], improving the therapeutic index of the entrapped drug [19], and protecting
APIs against their surrounding environment [20].
2. Cancer
Cancer is a life-threatening illness that leads to irregular and uncontainable growth of malignant
cells. These uncontrollable cells can invade normal tissues and organs, causing undesirable growth
and reactions that end up destroying them [21]. Cancer is responsible for ~3.4 million deaths
worldwide [22]. Some of the well-known causes for cancer disease are smoking (causing lung [23],
breast [24], and ovarian cancer [25]), being overweight or obese (associated with 13 types of cancer
disease, such as breast cancer, kidney, womb and bowel cancers), intake of processed meat [26],
radiation (causes skin cancer) [27], family history, stress, environmental factors, and chance [28].
Cancer cells are able to spread around the human body through blood vessels and lymphatic
streams, causing metastasis by forming a secondary tumour [29]. Anticancer agents are typically
administered to the patients to kill cancer cells. These drugs work in two ways: by killing the cancer
cells through direct exposure to the chemical agent and by inducing apoptosis (suicide of cancer
cells) [30].
Tumour vasculature is vital to preserving the tumour and aiding its growth [31]. It is characterised
by special physiological properties, being highly chaotic, complex, and porous in nature. Pore size
ranges between 100–780 nm, while normal tissue junctions are <6 nm [32]. The distance between
tumour cells should be within a certain limit of the perfused blood vessels in order to obtain the
required quantity of oxygen and nutrients to survive and proliferate [31]. Accordingly, tumours can
undergo extensive angiogenesis (the growth of new tumour blood vessels), grow beyond 1–2 mm in
diameter [31], and form hypervasculatures, which can be defective and impair the lymphatic drainage
systems. In addition to these properties, tumours can produce three known vascular-permeability
influences such as bradykinin, nitric oxide [33–35], and peroxynitrite [36]. Targeting the tumour
vasculature is essential for tumour treatment. This can be done by disturbing the angiogenesis using
antiangiogenic agents (eg, Axitinib (Inlyta®), Bevacizumab (Avastin®) and Cabozantinib (Cometriq®))
or shutting down the existing tumour blood flow, resulting in ischemia and tumour cell necrosis
using vascular targeting agents (eg, 5,6-dimethylxanthenone-4-acetic acid (flavonoid derivative) and
Combretastatin A-4 phosphate (tubulin binding drug) [37]. Accordingly, there is a high demand for
finding a proper controlled anticancer dosage to control this disease, as it is expected to be responsible
for 13.2 million death cases by 2030 [29].
Liposomal drug formulations offer the possibility of increasing efficacy while reducing the
toxic side effects of chemotherapeutic drugs. They can also impact the pharmacokinetics and tissue
distribution of the incorporated anticancer compound. They have been described as alternative DDSs
that have been used to enhance the therapeutic index and significantly reduce the toxic effect of
anticancer agents on normal tissues, including doxorubicin.
3. Categories of Liposomes
Numerous factors define liposomes properties such as the lipid composition, number of lipid
bilayers, size, surface charge, and the method of preparation [11]. Liposomal vesicles vary in size
between 0.025 µm to 2.5 µm. They can be categorised according to the number of their layers (also
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referred to as lamellae): unilamellar (consisting of single phospholipid bilayer) or multilamellar
(consisting of more than one unilamellar separated by layers of water [38] (>500 nm)). Unilamellar
vesicles are subdivided into small unilamellar vesicles (20–100 nm) and large unilamellar vesicles
(>100 nm). Both the size and the number of lamellae in the liposomal structure are considered to be the
most crucial factors affecting the vesicles half-life and the quantity of API that is to be encapsulated [11].
This unique and flexible variety in the liposomal structure distinguishes liposomes as the preferred
carriers for a broad spectrum of therapeutic agents.
4. Stability of Liposomes
Physical and chemical stability of the liposomes in terms of size distribution, entrapment efficiency,
and minimal degradation of liposomal apparatuses is the major limiting step for drug delivery using
this system. Chemical degradation of liposomes mainly occurs at the phospholipid bilayers level,
in which two different reactions might develop: (i) hydrolysis of the ester bonds between fatty acids
and glycerol backbone, and (ii) peroxidation of any available unsaturated acyl chain. These two
reactions might lead to the development of short-chain lipids; subsequently, soluble derivatives will
appear in the membrane that would significantly reduce the quality and stability of the liposomal
system [39]. With respect to physical instability, liposomes might undergo aggregation/flocculation
and fusion/coalescence, which can ultimately change vesicle size and lead to significant loss of the
encapsulated API [40].
Aqueous dispersions of liposomes suffer from elevated levels of instability due to the leakage of
the encapsulated drug out from the phospholipid bilayers. In addition to this, aggregation of liposomes
upon storage for a period exceeding the first few months of preparation was reported [41]. Accordingly,
it is more advisable to store liposomal preparations in solid form. Several methods are available
that show extendable techniques to stabilise the liposomal formulations, such as lyophilization [42],
spray drying [43], and supercritical fluid [44].
Several factors that have an influence on liposomal system stability, such as liposomal composition
(e.g., phospholipids-lipids with high phase transition temperatures), fatty acid side-chains, polar head
chemistry, chain length, and the degree of unsaturation, are preferred to maintain liposomal
rigidity [45] and phospholipid:cholesterol molar ratio (crucial for the liposomal stability and controlling
drug release). Briuglia et al. (2015) demonstrated that 70:30 molar ratio of phospholipids (using
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC),
and distearoyl phosphatidylcholine (DSPC)): cholesterol achieved a liposomal formulation that can
guarantee the stability and control over drug release [40] and surface potential (high surface potential
is directly related to the liposomal physical stability, as it helps to reduce the rate of fusion and
aggregation [46].
One of the reasons for liposomal aggregation is the vesicle–vesicle electrostatic effect between
the vesicles. Repulsive interactions, which are at least equal to the degree and range of the van der
Waals force, are an essential requirement for stable liposomal formulation [39]. The physical stability
of liposomes improves by increasing the surface charge density and reducing the ionic strength of
liposomes (increases the electrostatic repulsive energies), especially when phosphatidylcholine and
phosphatidylserine are used [46,47]. However, scientists need to consider all influencing factors
affecting liposomal stability and work around all of them. This is due to the fact these factors might be
affected by certain factors that can disrupt the system. For instance, electrostatic stabilisation is very
sensitive to the surface charge (pH) and salt concentration of the liposomal suspension. Electrostatic
stabilisation can be improved by combining it with the steric stabilisation (so called electrosteric
stabilisation), which can be obtained by covering the surface of the liposomes with an adsorbed coat of
long, bulky molecules (which, for example, keep the distance between the vesicles) [39].
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5. Influence of Liposomal Composition in Drug Delivery
Phospholipids are the main building blocks of liposomes. These biomolecules are also the main
components building the biological membranes. They are amphiphilic molecules that consist of a
polar head (water soluble hydroxy groups) and insoluble backbone. Liposomes can be zwitterionic,
positively or negatively charged, or uncharged. This is totally dependent on the polar head charge.
There are two types of lipids currently utilised for liposome preparation: naturally occurring or
synthesised double-chain lipids (consisting of phosphorus polar head and glycerol backbone) and
sterols (e.g., cholesterol) [48].
The most known lipids used in the liposomal formulations are phosphatidylcholine
(zwitterionic), phosphatidylglycerol (negatively charged), phosphatidic acid,
phosphatidylethanolamine (zwitterionic), and phosphatidylserine (negatively charged).
Positively charged lipids (e.g., N-[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA)
and 1,2-dioleoyl-3-trimethylammoniopropane (DOTAP)) are mainly used for gene delivery, as they
interact with the negatively charged deoxyribonucleic acid (DNA) [49] and negatively charged APIs.
Cholesterol is another strategic component of liposomes. It has a modulatory effect on the
properties of the lipid bilayer of the liposomes. It can control the stoutness in the liposome structure [40]
and increase the packing between the phospholipid molecules [50], resulting in more ordered
conformation in the aliphatic tail region, reduced micropolarity [51], reduced bilayer flexibility to the
surrounding molecules (especially water soluble molecules [52]), and increases in the microviscosity
of the bilayer [53]. Cholesterol is also crucial for structural stability of liposomal membranes against
intestinal environmental stress [51]. Cholesterol was found to influence liposomes size (increasing
cholesterol concentration increases liposomes size in addition to shape transition), provide permeability
and fluidity, and consequently modulate the release of hydrophilic compounds from liposomes [54].
It is also possible to use surface functionalisation of liposomes by a variety of agents to overcome
the limitations of these nanocarriers in terms of biological and physiological barriers [55]. For example,
liposomes can be functionalised with polyethylene glycols (PEGs), aptamers, antibodies, proteins,
peptides, ligands, carbohydrates, or small molecules (Figure 1) [55].
Figure 1. Structure of conventional and functionalised liposomes: (A) conventional liposomes
comprising phospholipids; (B) PEGylated/stealth liposomes containing a layer of polyethylene glycol
(PEG); (C) targeted liposomes containing a specific ligand to target a cancer site; and (D) multifunctional
liposomes, which can be used for diagnosis and treatment of solid tumours. Adapted from Creative
Commons Attribution License [55].
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6. Liposomes as Targeted Drug Delivery System for Cancer Treatment
Advancements in liposomal vesicle development have achieved both controlled drug release and
targeted drug delivery (disease-specific localisation). This property is essentially helpful for cancer
treatment as surgical resection, radiation therapy, and chemotherapy are the first-line treatment of
cancer. Some cancerous states require systemic administration of the chemotherapy. So far, most of the
APIs used in chemotherapy have been highly cytotoxic to cancer and normal cells. Therefore, they
suffer from plenty of side effects and limitations, as the free drug is administrated directly into the
blood stream that circulates the body. The chemotherapeutic agent can then be uptaken by cancer
and normal tissues, leading to severe toxicity to different body organs, such as heart, kidneys, liver,
and others. As a result, sometimes the highest possible dose of chemotherapy is administrated to the
patients to maximise the quantity of the medication taken up by the cancer cells [56]. The success of
cancer treatment basically depends on its capability to decrease the size and remove tumours without
affecting normal tissues, thus increasing patients’ survival time and enhancing their quality of life [29].
The encapsulation of chemotherapeutic agents within liposomal structures can limit the normal
tissue uptake of the medication and thus improve its therapeutic index. By means of passive
targeting, liposomes can concentrate preferentially on the tumour (typically over 24–48 h) via the
enhanced permeability and retention (EPR) effect of the vasculature, in which leaky tumour vessels
unite with absent lymph drainage [57]. In other words, passive targeting of liposomes happens
by transferring them into the tumour interstitium via leaky tumour vasculature through molecular
movement within fluids (Figure 2) [29]. Liposomes can actively target tumour tissues using the
antibody-based approach. This can be done by adding certain antibodies to the liposomal surface—so
called immunoliposomes (ILP)—which are specific to the cancer cells or to the endothelial cells of
the tumour vasculature [58]. Maruyama et al. (1999) developed the pendant type ILP (34A-PEG-ILP),
which is a long-circulating polyethylene glycol (PEG)-ILP attached to antibodies (34A antibody) at the
distal end of PEG chain. These ILPs showed high targetability to the site of action (lung endothelial
cells and tumour tissue)—more than ordinary liposomes. This is mainly caused by the effect of free
PEG, which successfully helped to avoid the RES uptake of the ILPs [59]. The limitation of this
approach is that not all tumour tissues or cells have a specific antigen for the targeted antibody to bind
to. Accordingly, this approach is limited to the antigen-antibody specifications.
Figure 2. Passive (A) and (B) active targeting of nanocarriers. Nanocarriers reach tumours selectively
through the leaky vasculature, or in other cases, where the nanocarrier size determines the retention in
the tumour tissue. Drugs in the absence of nanocarriers diffuse freely in and out the tumour blood
vessels due to their small size, and therefore their effective concentrations in the tumour decrease
rapidly. The EPR effect is where drug-loaded nanocarriers cannot diffuse back into the blood stream
due to their large size, resulting in progressive accumulation. In active targeting, ligands grafted at the
surface of nanocarriers bind to receptors (over)expressed by cancer cells or to angiogenic endothelial
cells. Adapted and reproduced with permission [3].
An additional targeting method has been developed that uses an external trigger to solve this
problem. This can be done by triggering the release of the chemotherapeutic agent within the
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interstitium after accumulating on the tumour tissue. This can be achieved by the effect of EPR
or by releasing the agent within the tumour vasculature using liposomes particularly designed to
respond to a precise external trigger (e.g., heat) [56,58]. For instance, thermosensitive liposomes that
can be administered systemically were developed.
There are several strategies by which local hyperthermia could improve the effectiveness of the
liposomal formulation for drug delivery: by inducing drug release at a temperature close to that of the
lipid phase transition of the liposomes, by promoting blood supply to the site of action, by improving
liposomes accumulation at the site of action by increasing endothelial permeability to liposomes,
by enhancing the permeability of the target cells to API that release from the liposomes, by enhancing
the fusion or endocytosis effect of target cells to the directly transferred drug from liposomes, and by
improving drug release from liposomes by reducing the local pH of the target site of action [60].
The first thermosensitive liposomes were developed by Yatvin et al. (1978), in which the formulation
used the two lipids DPPC:DSPC (molar ratio of 3:1), encapsulating neomycin (an aminoglycoside
antibiotic) as API. A local hyperthermia is then initiated (>40–42 ◦C), triggering drug release at
the targeted site [61]. The first animal test of an anticancer formulation using thermosensitive
liposomes was tested by Weinstein et al. in 1979. A mouse with lung cancer was treated with
methotrexate-encapsulated thermosensitive liposomes (DPPC:DSPC, 7:3 molar ratio). The results
showed a 4-fold increase of the drug quantity that reached the tumour tissue. However, the elimination
of the liposomes within 1 hour of administration was the major limitation of this formulation [60].
It was suggested by Magin et al. (1986) that the clearance and distribution of temperature-sensitive
liposomes is size-dependent. The size range of 50–200 nm was recommended [61], as the endothelium
tissues in the kidney glomerulus have a pore size of 40–60 nm. However, macrophages in liver
and spleen can easily remove these liposomes from blood circulation, as the pore size of sinusoidal
endothelium in liver and spleen is around 150 nm [29]. More studies demonstrated that vesicles
size, lipid composition, surface coating and charge [62], and liposome-plasma protein interaction
all have an impact on the clearance pharmacokinetics of liposomes by the reticuloendothelial
system [63]. Therefore, the selection of the most appropriate lipids (e.g., lysolipid temperature-sensitive
liposomes) [64], incorporation of cholesterol (to increase vesicles stability and reduce drug leakage) [65],
and the use of optimum polymers for coating [66] can help improve this DDS. For instance, coating
PEG onto liposomes is a helpful approach that can prevent liposome engulfment by the macrophages
and thus increase their blood circulation time. Maintaining an optimum hyperthermal effect is another
major limitation in clinical settings using thermosensitive liposomes, as it can result in overheating of
tissues. Magnetic liposomes-mediated unit chemotherapy and hyperthermal effect was developed as a
potential solution to overcome this problem. For instance, a novel magnetic liposomal formulation
for self-controlled hyperthermia and chemotherapy was designed by Gogoi et al. (2017). Liposomes
co-encapsulated with dextran-coated biphasic suspension of La0.75Sr0.25MnO3 (LSMO) and iron oxide
nanoparticles were developed using paclitaxel (PCX) as a model drug. Evaluation of the therapeutic
efficacy of the formulation showed a 2.5-fold (mean tumour volume 2356 ± 550 mm3) reduction of
the tumour growth after a single administration of the drug-loaded magnetic liposomes. A 3.6-fold
(mean tumour volume 1045 ± 440 mm3) reduction of the tumour growth after a double dose treatment
was reported as compared to the growth reduction effect of the corresponding control (mean tumour
volume 3782 ± 515 mm3). With no significant leaching of liposomes, biocompatibility and therapeutic
evaluation studies demonstrated the potential use of magnetic liposomal formulation for the treatment
of drug-resistant or physiologically vulnerable cancer [67]. The combination of chemotherapy and
thermotherapy was also reported using doxorubincin (DOX)-loaded magnetic liposomes (using citric
acid-coated magnetic nanoparticles). About 130 nm-sized magnetic liposomes were developed utilising
hydrogenated soy phosphatidylcholine (HSPC)/1,2-distearyl-sn-glycero-3-phosphoethanolamine
(DSPE)/cholesterol (12.5:1:8.25 molar ratio) and DOX by rotary evaporation and ultrasonication process.
In vitro cytotoxicity and hyperthermia studies evaluated against colorectal cancer revealed that the
magnetic liposomes displayed no cytotoxicity, with approximately 56% tumour cells being killed.
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This study demonstrates the effectiveness of the combination of hyperthermia and chemotherapy
treatment in one system as compared with individual treatment [68].
Another approach for the delivery of anticancer drugs is using enzyme-responsive liposomes.
The idea for this approach came after detecting high concentrations of certain enzymes in patients
diagnosed with cancer. For instance, some extracellular enzymes, e.g., secreted phospholipase A2
(sPLA2) (raises in prostate [69], breast [70] and pancreatic [71] cancers), matrix metalloproteinases
(MMPs) (specifically, MMP-2 and MMP-9 elevates in breast [72], colorectal [73], pancreatic [74],
and lung [75] tumours), urokinase plasminogen activator (uPA) (elevated in a number of human
cancers, such as breast, colon, bladder, and ovarian tumours) [76], elastase (found in high concentration
in cases of lung [77], breast [78], and skin [79] tumours), prostate-specific antigen (PSA) (raises in case
of prostate tumour) [80], and some intracellular enzymes, e.g., cathepsin B (elevated in brain, breast,
prostate, and lung cancer) [81,82].
PEGylated, sterically stabilised liposomes can stabilise the entrapped API, enhance activity, change
API disposition, and reduce toxicity [83]. However, they are unable to control their drug release
kinetics [84]. Over expression of the over-mentioned enzymes could be an effective target for controlling
drug release from liposomes [85]. This was reported for DOX-loaded sPLA2-responsive liposomes
developed by Mock et al. (2014) for the treatment of prostate cancer. Liposomes were prepared with
cholesterol, DSPC, DSPE, and (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)
2000)] (DSPE-PEG2000) (10 µmol total phospholipid). Animal tests showed that the liposomes were
1.5 to 2 times more effective than sterically stabilised liposomes (composed of DSPC, cholesterol, and
DSPE-PEG2000) at reducing tumour growth. The mechanisms mediating enzyme and drug uptake,
toxicity, and disposition of liposomes are cell- and formulation-dependent [86].
Cancer immunotherapy by vaccination is not yet a major type of treatment for cancer. However,
many scientists are searching for new approaches and formulations that could be effective in the
use of immunotherapy for cancer treatment or prevention. Allison and Gregoriadis were the first to
report the capability of liposomes to induce immune responses of entrapped antigens [87,88]. Several
types of cancer vaccines currently under investigation such as tumour cell vaccines, antigen vaccines,
dendritic cell vaccines, and vector-based vaccines. Depending on the chemical properties of materials
used in cancer vaccination, hydrophilic antigens (e.g., nucleic acids, peptides, carbohydrates, proteins,
and haptens) encapsulate within the aqueous phase of liposomes, whereas hydrophobic compounds
(e.g., antigens, linker molecules, lipopeptides, and adjuvants) are intercalated into the outer lipid
bilayer. Antigens and adjuvants, which are also lipophilic molecules, can be adsorbed or chemically
linked to the liposome surface [89]. For instance, a combination of Rituximab®and non-PEGylated
liposomal DOX are recommended as front-line therapy for the treatment of elderly patients (80 years
old) against aggressive non-Hodgkin lymphoma [90].
7. Applications of Liposomes in Anticancer Drug Formulations
Chemotherapeutics are the first line treatment approach for cancer. However, most of them are
limited due to unconcealed toxicity, poor selectivity of the right tissues, narrow therapeutic index,
and high probability of developing drug resistance. These factors can lead to dramatic failure in cancer
treatment. The development of nanoscale liposomal formulations has been shown to help the selective
transportation of the drug to the tumour cells [91]. This consequently avoids the off-target toxicity due
to the EPR effect [92]. Some liposomal-based DDS were approved by the FDA with potent anticancer
activity. Table 1 summarises some of the liposomal formulations used as cancer treatments.
DOX is an anthracycline antibiotic (isolated from Streptomyces peucetius var. caesius) with potent
anticancer activity that is widely used in the treatment of solid and hematologic neoplasms (such as
breast cancer and lymphoma) [93]. However, its clinical uses are limited by considerable cardiotoxicity
and cytotoxicity. The cardiotoxicity is usually cumulative and mostly leads to irreversible damage
to the cardiomyopathy and congestive heart failure, which is the result of generation of free radicals
and lipid peroxidation [93,94]. DOX can affect the DNA in several ways: (I) the cytotoxicity effect of
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DOX originates mostly from its intercalation that occurs at the DNA double helix minor groove level
through electrostatic interactions of sugar moieties with phosphate residues; (II) DOX has the potential
to stabilise DNA-topoisomerase II in a way that could prevent the DNA double helix resealing and
thus stop the cell replication process; and (III) by apoptosis, which can also be triggered by the DNA
break repair process [95].
Table 1. Liposomal formulations used as anticancer treatments.
Active
Ingredient Liposome Composition Size (nm)
Cancer
Type Being Targeted Reference
DOX HSPC/DSPE/cholesterol (12.5:1:8.25 molar ratio) 130 Colorectal(in-vitro) [68]
DOX Cholesterol, DSPC, DSPE and DSPE-PEG2000 (10 µmoltotal phospholipid). 100
Prostate cancer
(in-vivo/in-vitro [86]
DOX HSPC: cholesterol: lipid with a PEG head group(DSPE-PEG2000) (molar ratio 56.4:38.3:5.3) 100
Colorectal
(in-vitro) [68]
DOX 1-Palmitoyl-2-oleoylphosphatidylcholine: cholesterol(molar ratio 55.8:44.2) 180
Metastatic
(clinical trial & in clinic) [15,96]
DNR DSPC:cholesterol (molar ratio 2:1) 50 Kaposi’s sarcoma [97]
ATRA DPPC:cholesterol:1,2-distearoyl-sn-glycero-3-phosphoethanolamine- Methoxy PEG2000 (molar ratio 6:3:1) 200
Human Thyroid
carcinoma
(in-vitro)
[16]
ATRA DOTAP, cholesterol and ATRA (molar ratio 70:20:10) 263 Lung cancer(in-vivo in animal) [98]
MXT HSPC: DSPE-PEG2000: cholesterol: anacardic acid (molarratio 0.55:0.05:0.35:0.05) 112
Melanoma cell lines
(in-vitro) [99]
PCX Egg phosphatidylcholine: cholesterol: TPGS1000-TPP(molar ratio 88:3.5:8.5) 80
Lung cancer cell lines
(in-vivo & in-vitro) [30]
Irinotecan - - Pancreatic ductaladenocarcinoma [100]
Abbreviations: DPPC, dipalmitoyl phosphatidylcholine; DSPC, distearoyl phosphatidylcholine;
PCX, paclitaxel; LSMO, La0.75Sr0.25MnO3; DOX, doxorubincin; HSPC, hydrogenated soy
phosphatidylcholine; DSPE, 1,2-distearyl-sn-glycero-3-phosphoethanolamine; DSPE-PEG2000,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol) 2000]; DNR, daunorubicin:
ATRA, all-trans retinoic acid; DOTAP, 1,2-dioleoyl-3-trimethylammoniopropane; MXT, mitoxantrone;
DSPE2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-methoxy PEG2000; TPGS1000-TPP,
D-α-tocopheryl polyethylene glycol 1000 succinate-triphenylphosphine conjugate.
Doxil®, a PEGylated liposomal-based DOX (100 nm with 10,000–15,000 DOX per liposome),
was the first nano-drug to be approved by the FDA in 1995 for the treatment of AIDS-related Kaposi’s
sarcoma, in 1999 for the treatment of ovarian cancer, and in 2007 for the treatment of multiple
myeloma. The formulation is composed of hydrogenated soy phosphatidylcholine, cholesterol, and
a lipid with a PEG head group (DSPE-PEG2000) in 56.4:38.3:5.3 mole ratio [101]. It shows a potent
anticancer activity based on the following principles: (i) due to the use of PEGylated liposomes
that result in stealth formation (in which segments of methoxypolyethylene glycol (hydrophilic) are
attached onto the surface of each liposome (which covers 60% the liposomal surface)), this enables
the drug to last longer in the blood stream (3–4 days in humans), avoiding the RES and improving
the extravasation through endothelial gaps in tumours [102]; (ii) the “liquid ordered” of the lipidic
bilayer in the liposomes that consist of phosphatidylcholine (high melting point 53 ◦C) and cholesterol;
and (iii) efficient, high, and stable loading of doxorubicin in the liposomal formulation through
the effective use of the transmembrane ammonium sulfate gradient, allowing drug release at the
tumour site [103]. The main challenge for this formulation lies in having the maximum drug loading
efficiency during the manufacturing steps. PEGylated DOX hydrochloride liposome (PEGADRIA) was
developed by Ali et al. (2016) with a similar physiochemical profile to Doxil®. The only difference
between the formulations is that in PEGADRIA, DOX hydrochloride was used. PEGADRIA was
found to be safe and effective, as well as Doxil®, in the treatment of patients with ovarian cancer [104].
It is believed that PEGylation of the liposomal formulation Doxil®is the reason behind its toxicity.
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Myocet®is another liposomal-based, DOX citrate-encapsulated formulation (180 nm and composed of
1-palmitoyl-2-oleoylphosphatidylcholine:cholesterol, mole ratio 55.8:44.2), but it lacks the PEGylated
coating. It is characterised by a shorter circulation time compared with Doxil®, with dramatically
reduced cardiac toxicity [15,96].
Daunorubicin (DNR) is another anthracycline antibiotic (isolated from Streptomyces peucetius
varcaesitue) drug with anticancer activity [97]. It works the same as DOX with significant side effects,
such as cardiotoxicity (dose-dependent), alopecia, nausea, and vomiting, which are associated with
DNR therapy, but liposomal daunorubicin formulation has been developed as an alternative to
reduce some of these adverse side effects. Liposomal DNR (DaunoXome®), 50 nm in size and
composed of DSPC:cholesterol in a molar ratio of 2:1, was the only first-line therapy for the treatment
of advanced HIV-associated Kaposi’s sarcoma [105], approved by the FDA in 1996. It was designed to
be phagocytosed by monocytes in the blood circulation. Its small size and the fact it is uncharged help
to minimise RES uptake and consequently to prolong drug circulation time [97]. The most prominent
side effect of this formulation is severe leukopenia [106] and neutropenia in some cases [107]. The use
of this formulation in treatment has shown higher levels of plasma DNR in treated mice compared
to the free drug. Likewise, the clearance of the free drug was shown to be 44.9 mL/h, while the
liposomal formulation was 0.195 mL/h, demonstrating a very slow clearance rate of the DaunoXome®.
In another related study, it was reported that DaunoXome®displayed a favorable cardiac toxicity
profile, also allowing an increased anthracycline dose without increasing cardiotoxicity [108]. Treating
patients with Kaposi sarcoma using liposomal DNR formulation at a dose of up to 1700 mg/m2
showed no cardiotoxicity [105].
All-trans retinoic acid (ATRA) is an anti-tumour agent characterised by different anti-cancer
activities against several types of cancer cells [16]. Due to its common side effects (burning of the skin
and general malaise) after systemic administration, having a highly variable degree of bioavailability,
and its propensity to induce its own metabolic degradation after oral administration, an alternative
pharmaceutical formulation is required. Negatively-surface charged ATRA-loaded liposomes
(∼200 nm) made up of DPPC/cholesterol/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-methoxy
PEG2000 (6:3:1 molar ratio) were developed and investigated against three different human thyroid
carcinoma cell lines (PTC-1, B-CPAP and FRO) (Figure 3). These liposomes were found to protect ATRA
against photodegradation and enhance its antiproliferative properties, promoting them to be a novel
formulation for the treatment of anaplastic thyroid carcinoma [16]. ATRA was also encapsulated within
cationic liposomes aiming for the treatment of lung cancer. In the formulation composed of DOTAP,
cholesterol, and ATRA (70:20:10 molar ratio), liposomes (263 nm) contained ca. 92% of entrapped drug,
and animal tests showed significant high bioavailability in lung and blood. As compared with free
drug, a higher half-life of 14.8 vs. 13.2 h), Cmax (0.66 vs. 0.29 µg/mL), and a lower clearance (46.6 vs.
136.3 µg/mL/h) in vivo was reported for the liposomal formulation demonstrating the potential for
lung cancer treatment [98].
Mitoxantrone (MXT) (1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthra-
cenedione dihydrochloride) is an anthracenedione antineoplastic drug. It is commonly utilised for
the treatment of several types of cancer such as lymphomas, breast cancer, prostate cancers, and
leukemias [109]. It has been proposed that it works by numerous mechanisms of action: intercalation,
calcium release, electrostatic interactions with DNA, inhibition of topoisomerase II, DNA-protein
cross-links, immunosuppressive activities, and inhibition of prostaglandin biosynthesis by interfering
with the regulatory process, which is dependent on the hydroperoxy fatty acid [110]. Animal studies
suggested that free MXT has also cardiotoxic potential. However, the drug leads to less severe cardiac
damage than free DOX, as it acts using a different mechanism [111]. MXT liposomes intended for the
treatment of lymphoma and breast cancer are still in phase II trials. An animal study was conducted
by Wang et al. (2010) to compare the pharmacodynamics, pharmacokinetics, and tissue distribution
of MXT loaded-liposomal and free MXT. It was found that from the pharmacodynamic studies,
that MXT loaded-liposomes inhibited tumour growth (at a dose of 1 to 4 mg kg-1); from the antitumour
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effect studies that MXT loaded-liposomes enhanced the therapeutic effect of the drug significantly
in comparison with free MXT; from the pharmacokinetic studies that MXT loaded-liposomes had
longer circulation characteristics as compared with free MXT at the same dose; and from tissue
distribution studies that MXT loaded-liposomes accumulated into tumour zones rather than normal
tissues. The overall studies suggested that the therapeutic effect and MXT therapeutic index could be
improved by using MXT loaded-liposomes [19]. Another liposomal formulation developed by Legut
et al. (2014) suggested the addition of anacardic acid improved the encapsulation and retention of
MXT. A liposomal formulation composed of HSPC: DSPE-PEG2000: cholesterol: anacardic acid in
molar ratio of 0.55:0.05:0.35:0.05 was stable for 6 months, with over 90% encapsulation efficiency in
5 min. The formulation showed anticancer activity towards melanoma cell lines. The cytotoxicity of
MXT was also improved [99].
Figure 3. (A) Confocal laser scanning micrograph showing the interaction between fluorescein-labeled
liposomes and FRO cells after 6 h incubation (bar = 35 µm) and (B) intracellular uptake of ATRA as
free form or entrapped in liposomes within FRO cells as a function of the incubation time. Reproduced
with permission [16]. * p < 0.05, ** p < 0.01.
PCX is a naturally occurring compound extracted from Taxus brevifolia [30]. PCX has an anticancer
activity against several cancers including refractory ovarian, breast, non-small cell lung cancer,
gastric cancer [112], head and neck tumours, urologic malignancies, and Kaposi’s sarcoma [113].
This alkaloid compound works by a unique mechanism of action. During the mitotic phase
of cell division, PCX promotes polymerisation of cancer cells tubulin proteins, disturbing their
dynamic, stabilising their microtubules, making them dysfunctional, and, finally, leading to cell
death. However, PCX anticancer activity is limited due to its highly lipophilicity (log P value of 3.96)
and very poor water solubility (<0.01 mg/mL) [113]. Taxol®is the pharmaceutical formulation of
PCX administrated in a non-aqueous base vehicle. It has caused severe hypersensitivity reaction to
patients as a result of Cremophor EL in the formulation in addition to the precipitation on aqueous
dilution [114]. Accordingly, the encapsulation of this active agent can be helpful for targeting the
cancer cells. PCX loaded liposomes are designed to target and accumulate at the mitochondria in
cancer cells using D-α-tocopheryl polyethylene glycol 1000 succinate-triphenylphosphine conjugate
(TPGS1000-TPP) as a mitochondrial targeting compound. The liposomal formulation is composed
of egg phosphatidylcholine, cholesterol, and TPGS1000-TPP in molar ratio of 88:3.5:8.5, respectively.
Administration of this formulation (>85% encapsulation efficiency) showed the strongest inhibitory
effect on tumour cells’ growth at day 26 (73.14% of tumour volume inhibitory rate). The small particle
size (80 nm) of liposomes in addition time and to TPGS1000-TPP conjugate at the liposome membrane
both played a role in enhancing the circulation escape of the rapid elimination by RES. Moreover,
PCX liposomes triggered apoptosis of drug-resistant lung cancer by stimulating the pro-apoptotic
Bax and Bid proteins and suppressing the anti-apoptotic Bcl-2 protein (Figure 4) [30]. A comparison
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study was conducted to evaluate the efficacy and safety of PCX liposome (Lipusu®) and free PCX on
patients suffering from gastric cancer. Patients received other chemotherapeutic agents (tegafur and
oxaliplatin usually described for patients with advanced gastric cancer) at the same time in the study.
Both formulations showed almost the same hematological and neurological toxicities (P > 0.05), while
significant reductions on PCX side effects (e.g., nausea, hypersensitivity reactions, and vomiting) were
reported for patients receiving the PCX liposomal formulation [112].
Figure 4. Imaging and release rates of paclitaxel (PCX) liposomes: (A) transmission electron microscopy
images of PCX liposomes and targeting PCX liposomes, (B) atomic force microscopy images of PCX
liposomes and targeting PCX liposomes, and (C) release rates (%) of PCX-loaded liposomes in the
release media of pH 7.4 PBS containing 10% fetal bovine serum (mean ± standard deviation (n = 3).
Reproduced with permission [30].
Wang-Gallam et al. (2018) report the findings of a global, phase 3, randomised, open-label trial at
76 sites in 14 countries with patients with metastatic pancreatic ductal adenocarcinoma [100]. This study
(NAPOLI-1) assessed the effect of a nanoliposomal formulation of irinotecan, alone and in combination
with fluorouracil (FU) and folinic acid (FA). The nanoliposomal irinotecan formulated with the FU
and FA combination extended the survival of patients with the disease whom had previously received
gemcitabine-based therapy, thereby opening a new treatment option.
In summary, liposomes offer an attractive vehicle for targeted delivery of anticancer agents.
These nanocarriers overcome the undesirable side effects that range from simple headache
to cytotoxicity in normal tissues and increase circulation time, bioavailability, and target-site
drug concentration accumulation; they also reduce elimination and toxicity, and protect the
chemotherapeutic agents from the surrounding environment, in addition to carrying them to the
desired site of action. Liposomes may be surface-functionalised using a range of biomolecules to
achieve the required receptor-specific targeting [115].
Molecules 2018, 23, 907 12 of 17
Acknowledgments: The authors would like to acknowledge the support from the Federal Ministry of Agriculture
and Rural Development. All sources of funding of the study should be disclosed. Please clearly indicate grants
that you have received in support of your research work. Clearly state if you received funds for covering the costs
to publish in open access.
Author Contributions: Temidayo O. B. Olusanya: Wrote the first draft, collected the relevant articles to be
included. Rita Rushdi Haj Ahmad: Collected relevant articles and mapped the information within the article with
those in the corresponding literature. Daniel M. Ibegbu: Helped in writing the article and collected some of the
relevant literature James R. Smith: Revised the manuscript, gained the permission for the figures that are included
in the review article, proofread the whole article and also he chose the included figures. Amal Ali Elkordy:
Gave the idea for the topic of this review article, arranged the subtitles of the article and agreeing with distribution
of the work required to all other authors. Responsible for the correspondance with molecules journal.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Kumar, A.; Chen, F.; Mozhi, A.; Zhang, X.; Zhao, Y.; Xue, X.; Hao, Y.; Zhang, X.; Wang, P.C.; Liang, X.J.
Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.
Nanoscale 2013, 5, 8307–8325. [CrossRef] [PubMed]
2. Allen, T.M.; Cullis, P.R. Drug Delivery Systems: Entering the Mainstream. Science 2004, 303, 1818–1822.
[CrossRef] [PubMed]
3. Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting
of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135–146. [CrossRef] [PubMed]
4. Kieler-Ferguson, H.M.; Chan, D.; Sockolosky, J. Encapsulation, controlled release, and antitumor efficacy of
cisplatin delivered in liposomes composed of sterol-modified phospholipids. Eur. J. Pharm. Sci. 2017, 130,
85–93. [CrossRef] [PubMed]
5. Balzus, B.; Sahle, F.F.; Hönzke, S.; Gerecke, C.; Schumacher, F.; Hedtrich, S.; Kleuser, B.; Bodmeier, R.
Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of corticosteroids to
the skin and the corneal epithelium. Eur. J. Pharm. Biopharm. 2017, 115, 122–130. [CrossRef] [PubMed]
6. Mehta, P.; Al-Kinani, A.A.; Haj-Ahmad, R.; Arshad, M.S.; Chang, M.W.; Alany, R.G.; Ahmad, Z. Electrically
atomised formulations of timolol maleate for direct and on-demand ocular lens coatings. Eur. J. Pharm.
Biopharm. 2017, 119, 170–184. [CrossRef] [PubMed]
7. Chen, M.J.; Hui, H.-W.; Lee, T.; Kurtulik, P.; Surapaneni, S. Nanosuspension of a Poorly Soluble Drug via
Microfluidization Process. U.S. Patent 9,023,886, 10 November 2009.
8. Takechi-Haraya, Y.; Goda, Y.; Sakai-Kato, K. Control of liposomal penetration into three-dimensional
multicellular tumor spheroids by modulating liposomal membrane rigidity. Mol. Pharm. 2017, 14, 2158–2165.
[CrossRef] [PubMed]
9. Bangham, A.D. Physical structure and behavior of lipids and lipid enzymes. Adv. Lipid Res. 1963, 1, 65–104.
[PubMed]
10. Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S.Y.; Sood, A.K.; Hua, S. Advances and challenges of liposome
assisted drug delivery. Front. Pharmacol. 2015, 6, 286. [CrossRef] [PubMed]
11. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.;
Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett.
2013, 8, 102. [CrossRef] [PubMed]
12. Mohammed, A.R.; Weston, N.; Coombes, A.G.A.; Fitzgerald, M.; Perrie, Y. Liposome formulation of poorly
water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int. J. Pharm. 2004, 285,
23–34. [CrossRef] [PubMed]
13. Mukherjee, B.; Patra, B.; Layek, B.; Mukherjee, A. Sustained release of acyclovir from nano-liposomes and
nano-niosomes: An in vitro study. Int. J. Nanomed. 2007, 2, 213–225.
14. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol.
Sci. 1994, 15, 215–220. [CrossRef]
15. Allen, T.M.; Martin, F.J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. 2004, 31,
5–15. [CrossRef] [PubMed]
Molecules 2018, 23, 907 13 of 17
16. Cristiano, M.C.; Cosco, D.; Celia, C.; Tudose, A.; Mare, R.; Paolino, D.; Fresta, M. Anticancer activity of
all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells. Colloids Surf. B: Biointerfaces 2017,
150, 408–416. [CrossRef] [PubMed]
17. Allen, T.M.; Cheng, W.W.; Hare, J.I.; Laginha, K.M. Pharmacokinetics and pharmacodynamics of lipidic
nano-particles in cancer. Anticancer Agents Med. Chem. 2006, 6, 513–523. [CrossRef] [PubMed]
18. Matsuo, H.; Wakasugi, M.; Takanaga, H.; Ohtani, H.; Naito, M.; Tsuruo, T.; Sawada, Y. Possibility of the
reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a
monoclonal antibody to P-glycoprotein. J. Control. Release 2001, 77, 77–86. [CrossRef]
19. Wang, C.X.; Li, C.L.; Zhao, X.; Yang, H.Y.; Wei, N.; Li, Y.-H.; Zhang, L.; Zhang, L. Pharmacodynamics,
pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride. Yao Xue Xue Bao 2010,
45, 1565–1569. [PubMed]
20. Park, K.; Kwon, I.C.; Park, K. Oral protein delivery: Current status and future prospect. React. Funct. Polym.
2011, 71, 280–287. [CrossRef]
21. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc Health Risk Manag.
2006, 2, 213–219. [CrossRef] [PubMed]
22. Hooper, L.; Anderson, A.S.; Birch, J.; Forster, A.S.; Rosenberg, G.; Bauld, L.; Vohra, J. Public awareness
and healthcare professional advice for obesity as a risk factor for cancer in the UK: a cross-sectional survey.
J. Public Health 2017, 1–9. [CrossRef] [PubMed]
23. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CACancer
J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
24. Conway, K.; Edmiston, S.N.; Parrish, E.; Bryant, C.; Tse, C.K.; Swift-Scanlan, T.; McCullough, L.E.; Kuan, P.F.
Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.
Breast Cancer Res. Treat. 2017, 163, 349–361. [CrossRef] [PubMed]
25. Licaj, I.; Jacobsen, B.K.; Selmer, R.M.; Maskarinec, G.; Weiderpass, E.; Gram, I.T. Smoking and risk of ovarian
cancer by histological subtypes: An analysis among 300,000 Norwegian women. Br. J. Cancer 2017, 116,
270–276. [CrossRef] [PubMed]
26. Vineis, P.; Stewart, B.W. How do we judge what causes cancer? The meat controversy. Int. J. Cancer 2016, 138,
2309–2311. [CrossRef] [PubMed]
27. Revenco, T.; Lapouge, G.; Moers, V.; Brohée, S.; Sotiropoulou, P.A. Low dose radiation causes skin cancer in
mice and has a differential effect on distinct epidermal stem cells. Stem Cells 2017, 35, 1355–1364. [CrossRef]
[PubMed]
28. Dumalaon-Canaria, J.A.; Hutchinson, A.D.; Prichard, I.; Wilson, C. What causes breast cancer? A systematic
review of causal attributions among breast cancer survivors and how these compare to expert-endorsed risk
factors. Cancer Causes Control 2014, 25, 771–785. [CrossRef] [PubMed]
29. Gogoi, M.; Kumar, N.; Patra, S. Multifunctional magnetic liposomes for cancer imaging and therapeutic
applications. In Nanoarchitectonics Smart Delivery Drug Targeting; Holban, A.M., Grumezescu, G., Eds.;
Elsevier: Amsterdam, The Netherlands, 2016; pp. 743–782.
30. Zhou, J.; Zhao, W.-Y.; Ma, X.; Ju, R.J.; Li, X.Y.; Li, N.; Sun, M.G.; Shi, J.F.; Zhang, C.X.; Lu, W.L. The anticancer
efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Biomaterials 2013, 34, 3626–3638. [CrossRef] [PubMed]
31. Forster, J.C.; Harriss-Phillips, W.M.; Douglass, M.J.; Bezak, E. A review of the development of tumor
vasculature and its effects on the tumor microenvironment. Hypoxia 2017, 5, 21–32. [CrossRef] [PubMed]
32. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for
delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51, 691–743. [PubMed]
33. Maeda, H.; Noguchi, Y.; Sato, K.; Akaike, T. Enhanced vascular permeability in solid tumor is mediated by
nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Cancer Sci.
1994, 85, 331–334. [CrossRef]
34. Maeda, H.; Matsumura, Y.; Kato, H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic
fluid from a patient with gastric cancer. J. Biol. Chem. 1988, 263, 16051–16054. [PubMed]
35. Matsumura, Y.; Kimura, M.; Yamamoto, T.; Maeda, H. Involvement of the kinin-generating cascade in
enhanced vascular permeability in tumor tissue. Cancer Sci. 1988, 79, 1327–1334. [CrossRef]
36. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in
macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284. [CrossRef]
Molecules 2018, 23, 907 14 of 17
37. Pilat, M.J.; McCormick, J.; LoRusso, P.M. Vascular targeting agents. Curr. Oncol. Rep. 2004, 6, 103–110.
[CrossRef] [PubMed]
38. Shaheen, S.M.; Shakil Ahmed, F.R.; Hossen, M.N.; Ahmed, M.; Amran, M.S.; Ul-Islam, M.A. Liposome as a
carrier for advanced drug delivery. Pak J. Biol. Sci. 2006, 9, 1181–1191.
39. Yadav, A.; Murthy, M.S.; Shete, A.S.; Sakhare, S. Stability aspects of liposomes. Indian J. Pharm. Educ. Res.
2011, 45, 402–413.
40. Briuglia, M.-L.; Rotella, C.; McFarlane, A.; Lamprou, D.A. Influence of cholesterol on liposome stability and
on in vitro drug release. Drug Deliv. Transl. Res. 2015, 5, 231–242. [CrossRef] [PubMed]
41. Ghanbarzadeh, S.; Valizadeh, H.; Zakeri-Milani, P. The Effects of Lyophilization on the Physico-Chemical
Stability of Sirolimus Liposomes. Adv. Pharm. Bull. 2013, 3, 25–29. [PubMed]
42. Ball, R.L.; Bajaj, P.; Whitehead, K.A. Achieving long-term stability of lipid nanoparticles: Examining the
effect of pH, temperature, and lyophilization. Int. J. Nanomed. 2016, 12, 305–315. [CrossRef] [PubMed]
43. Patil-Gadhe, A.; Pokharkar, V. Single step spray drying method to develop proliposomes for inhalation:
A systematic study based on quality by design approach. Pulm. Pharmacol. Ther. 2014, 27, 197–207. [CrossRef]
[PubMed]
44. Karn, P.R.; Cho, W.; Park, H.-J.; Park, J.-S.; Hwang, S.-J. Characterization and stability studies of a novel
liposomal cyclosporin A prepared using the supercritical fluid method: Comparison with the modified
conventional Bangham method. Int. J. Nanomed. 2013, 8, 365–377.
45. Ceh, B.; Lasic, D.D. A rigorous theory of remote loading of drugs into liposomes. Langmuir 1995, 11,
3356–3368. [CrossRef]
46. Crommelin, D.J. Influence of lipid composition and ionic strength on the physical stability of liposomes.
J. Pharm. Sci. 1984, 73, 1559–1563. [CrossRef] [PubMed]
47. Frokjaer, S.; Hjorth, E.L.; Worts, O. Stability and storage of liposomes. In Optimization of Drug Delivery;
Bundgaard, H., Bagger Hansen, A., Kofod, H., Eds.; Munkgaard: Copenhagen, Denmark, 1982.
48. Chawdhury, D.F. Pharmaceutical Nanosystems: Manufacture, characterisation and safety. In Pharmaceutical
Manufacturing Handbook: Production and Processes; Gad, S.C., Ed.; John Wiley and Sons. Inc.: Hoboken, NJ,
USA, 2008; pp. 1286–1326.
49. Munye, M.M.; Ravi, J.; Tagalakis, A.D.; McCarthy, D.; Ryadnov, M.G.; Hart, S.L. Role of liposome and peptide
in the synergistic enhancement of transfection with a lipopolyplex vector. Sci. Rep. 2015, 5, 9292. [CrossRef]
[PubMed]
50. Demel, R.A.; de Kruyff, B. The function of sterols in membranes. Biochim. Biophys. Acta BBA-Biomembr. 1976,
457, 109–132. [CrossRef]
51. Liu, W.; Wei, F.; Ye, A.; Tian, M.; Han, J. Kinetic stability and membrane structure of liposomes during in vitro
infant intestinal digestion: Effect of cholesterol and lactoferrin. Food Chem. 2017, 230, 6–13. [CrossRef]
[PubMed]
52. Garg, T.; Goyal, A.K. Liposomes: Targeted and Controlled Delivery System. Drug Del. Lett. 2014, 4, 62–71.
[CrossRef]
53. Cogan, U.; Shinitzky, M.; Weber, G.; Nishida, T. Microviscosity and order in the hydrocarbon region of
phospholipid and phospholipid-cholesterol dispersions determined with fluorescent probes. Biochemistry.
1973, 12, 521–528. [CrossRef] [PubMed]
54. Kaddah, S.; Khreich, N.; Kaddah, F.; Charcosset, C.; Greige-Gerges, H. Cholesterol modulates the liposome
membrane fluidity and permeability for a hydrophilic molecule. Food Chem. Toxicol. 2018, 113, 40–48.
[CrossRef] [PubMed]
55. Riaz, M.K.; Riaz, M.A.; Zhang, X.; Lin, C.; Wong, K.H.; Chen, X.; Zhang, G.; Lu, A.; Yang, Z. Surface
functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int. J. Mol. Sci.
2018, 19, 195. [CrossRef] [PubMed]
56. Motamarry, A.; Asemani, D.; Haemmerich, D. Thermosensitive Liposomes. In Liposomes; Catala, A., Ed.;
InTech: Rijeka, Croatia, 2017.
57. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of
tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189–207. [CrossRef]
58. Kunjachan, S.; Ehling, J.; Storm, G.; Kiessling, F.; Lammers, T. Noninvasive imaging of nanomedicines
and nanotheranostics: Principles, progress, and prospects. Chem. Rev. 2015, 115, 10907–10937. [CrossRef]
[PubMed]
Molecules 2018, 23, 907 15 of 17
59. Maruyama, K.l.; Ishida, O.; Takizawa, T.; Moribe, K. Possibility of active targeting to tumor tissues with
liposomes. Adv. Drug Deliv. Rev. 1999, 40, 89–102. [CrossRef]
60. Weinstein, J.N.; Magin, R.L.; Yatvin, M.B.; Zaharko, D.S. Liposomes and local hyperthermia: Selective
delivery of methotrexate to heated tumors. Science 1979, 204, 188–191. [CrossRef] [PubMed]
61. Yatvin, M.B.; Weinstein, J.N.; Dennis, W.H.; Blumenthal, R. Design of liposomes for enhanced local release of
drugs by hyperthermia. Science 1978, 202, 1290–1293. [CrossRef] [PubMed]
62. Senior, J.H. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit. Rev. Ther. Drug
Carrier Syst. 1987, 3, 123–193. [PubMed]
63. Cullis, P.R.; Chonn, A.; Semple, S.C. Interactions of liposomes and lipid-based carrier systems with blood
proteins: Relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 1998, 32, 3–17. [PubMed]
64. Kong, G.; Anyarambhatla, G.; Petros, W.P.; Braun, R.D.; Colvin, O.M.; Needham, D.; Dewhirst, M.W.
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug
release. Cancer Res. 2000, 60, 6950–6957. [PubMed]
65. Gaber, M.H.; Hong, K.; Huang, S.K.; Papahadjopoulos, D. Thermosensitive sterically stabilized liposomes:
formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.
Pharm. Res. 1995, 12, 1407–1416. [CrossRef] [PubMed]
66. Kono, K.; Zenitani, K.; Takagishi, T. Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol)
derivative with carboxyl groups. Biochim. Biophys. Acta. 1994, 1193, 1–9. [CrossRef]
67. Gogoi, M.; Jaiswal, M.K.; Sarma, H.D.; Bahadur, D.; Banerjee, R. Biocompatibility and therapeutic evaluation
of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy. Integr. Biol.
2017, 9, 555–565. [CrossRef] [PubMed]
68. Hardiansyah, A.; Huang, L.-Y.; Yang, M.-C.; Liu, T.Y.; Tsai, S.C.; Yang, C.Y.; Kuo, C.Y.; Chan, T.Y.; Zou, H.M.;
Lian, W.N.; et al. Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field
treatment. Nanoscale Res. Lett. 2014, 9, 497. [CrossRef] [PubMed]
69. Graff, J.R.; Konicek, B.W.; Deddens, J.A.; Chedid, M.; Hurst, B.M.; Colligan, B.; Neubauer, B.L.; Carter, H.W.;
Carter, J.H. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
Clin. Cancer Res. 2001, 7, 3857–3861. [PubMed]
70. Yamashita, S.; Yamashita, J.; Sakamoto, K.; Inada, K.; Nakashima, Y.; Murata, K.; Saishoji, T.; Nomura, K.;
Ogawa, M. Increased expression of membrane-associated phospholipase A2 shows malignant potential of
human breast cancer cells. Cancer 1993, 71, 3058–3064. [CrossRef]
71. Kiyohara, H.; Egami, H.; Kako, H.; Shibata, Y.; Murata, K.; Ohshima, S.; Sei, K.; Suko, S.; Kurano, R.;
Ogawa, M. Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas.
Int. J. Pancreatol. 1993, 13, 49–57. [PubMed]
72. La Rocca, G.; Pucci-Minafra, I.; Marrazzo, A.; Taormina, P.; Minafra, S. Zymographic detection and clinical
correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 2004, 90, 1414–1421. [CrossRef]
[PubMed]
73. Mook, O.R.F.; Frederiks, W.M.; van Noorden, C.J.F. The role of gelatinases in colorectal cancer progression
and metastasis. Biochim. Biophys. Acta BBA-Rev. Cancer 2004, 1705, 69–89. [CrossRef] [PubMed]
74. Keleg, S.; Büchler, P.; Ludwig, R.; Büchler, M.W.; Friess, H. Invasion and metastasis in pancreatic cancer. Mol.
Cancer 2003, 2, 14. [CrossRef] [PubMed]
75. Osinsky, S.P.; Ganusevich, I.I.; Bubnovskaya, L.N.; Valkovskaya, N.V.; Kovelskaya, A.V.; Sergienko, T.K.;
Zimina, S.V. Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma:
correlation with metastasis. Exp. Oncol. 2005, 27, 202–205. [PubMed]
76. Liu, S.; Bugge, T.H.; Leppla, S.H. Targeting of tumor cells by cell surface urokinase plasminogen
activator-dependent anthrax toxin. J. Biol. Chem. 2001, 276, 17976–17984. [CrossRef] [PubMed]
77. Moroy, G.; Alix, A.J.P.; Sapi, J.; Hornebeck, W.; Bourguet, E. Neutrophil elastase as a target in lung cancer.
Anticancer Agents Med. Chem. 2012, 12, 565–579. [CrossRef] [PubMed]
78. Yamashita, J.; Ogawa, M.; Shirakusa, T. Free-form neutrophil elastase is an independent marker predicting
recurrence in primary breast cancer. J. Leukoc. Biol. 1995, 57, 375–378. [CrossRef] [PubMed]
79. Starcher, B.; O’Neal, P.; Granstein, R.D.; Beissert, S. Inhibition of neutrophil elastase suppresses the
development of skin tumors in hairless mice. J. Invest. Dermatol. 1996, 107, 159–163. [CrossRef] [PubMed]
Molecules 2018, 23, 907 16 of 17
80. Denmeade, S.R.; Sokoll, L.J.; Chan, D.W.; Khan, S.R.; Isaacs, J.T. Concentration of enzymatically active
prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human
prostate cancer xenograft models. Prostate 2001, 48, 1–6. [CrossRef] [PubMed]
81. Gondi, C.S.; Rao, J.S. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 2013, 17, 281–291. [CrossRef]
[PubMed]
82. Fouladi, F.; Steffen, K.J.; Mallik, S. Enzyme-responsive liposomes for the delivery of anticancer drugs.
Bioconjug. Chem. 2017, 28, 857–868. [CrossRef] [PubMed]
83. Arnold, R.D.; Mager, D.E.; Slack, J.E.; Straubinger, R.M. Effect of repetitive administration of
Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain
tumor model. Clin. Cancer Res. 2005, 11, 8856–8865. [CrossRef] [PubMed]
84. Drummond, M.F.; Mason, A.R. European perspective on the costs and cost-effectiveness of cancer therapies.
J. Clin. Oncol. 2007, 25, 191–195. [CrossRef] [PubMed]
85. Yamashita, S.; Yamashita, J.; Ogawa, M. Overexpression of group II phospholipase A2 in human breast
cancer tissues is closely associated with their malignant potency. Br. J. Cancer 1994, 69, 1166–1170. [CrossRef]
[PubMed]
86. Mock, J.N.; Costyn, L.J.; Wilding, S.L.; Arnold, R.D.; Cummings, B.S. Evidence for distinct mechanisms
of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer.
Integr. Biol. 2013, 5, 172–182. [CrossRef] [PubMed]
87. Allison, A.C.; Gregoriadis, G. Liposomes as immunological adjuvants. Nature 1974, 252, 252. [CrossRef]
[PubMed]
88. Allison, A.C.; Gregoriadis, G. Liposomes as Immunological Adjuvants. In Lymphocytes, Macrophages, and
Cancer; Recent Results in Cancer Research/Fortschritte der Krebsforschung/Progrès dans les recherches
sur le cancer; Mathe, G., Florentin, I., Simmler, M.S., Eds.; Springer: Berlin/Heidelberg, Germany, 1976;
pp. 58–64.
89. Schwendener, R.A. Liposomes as vaccine delivery systems: A review of the recent advances.
Ther. Adv. Vaccines 2014, 2, 159–182. [CrossRef] [PubMed]
90. Ricciuti, G.; Finolezzi, E.; Luciani, S.; Ranucci, E.; Federico, M.; Di Nicola, M.; Zecca, I.A.L.; Angrilli, F.
Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for
aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective
study. Hematol. Oncol. 2018, 36, 44–48. [CrossRef] [PubMed]
91. Kang, C.; Sun, Y.; Zhu, J.; Li, W.; Zhang, A.; Kuang, T.; Xie, J.; Yang, Z. Delivery of nanoparticles for treatment
of brain tumor. Curr. Drug Metab. 2016, 17, 745–754. [CrossRef] [PubMed]
92. Kang, C.; Sun, Y.; Wang, M.; Cheng, X. Nanosized camptothecin conjugates for single and combined drug
delivery. Eur. J. Biomed. Res. 2016, 2, 8–14. [CrossRef]
93. Tahover, E.; Patil, Y.P.; Gabizon, A.A. Emerging delivery systems to reduce doxorubicin cardiotoxicity and
improve therapeutic index: focus on liposomes. Anticancer Drugs 2015, 26, 241–258. [CrossRef] [PubMed]
94. Mostafa, M.G.; Mima, T.; Ohnishi, S.T.; Mori, K. S-allylcysteine ameliorates doxorubicin toxicity in the heart
and liver in mice. Planta Med. 2000, 66, 148–151. [CrossRef] [PubMed]
95. Tewey, K.M.; Rowe, T.C.; Yang, L.; Halligan, B.D.; Liu, L.F. Adriamycin-induced DNA damage mediated by
mammalian DNA topoisomerase II. Science 1984, 226, 466–468. [CrossRef] [PubMed]
96. Safra, T. Cardiac Safety of Liposomal Anthracyclines. Oncologist 2003, 8, 17–24. [CrossRef] [PubMed]
97. Petre, C.E.; Dittmer, D.P. Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int. J. Nanomed. 2007, 2,
277–288.
98. Berlin Grace, V.M.; Viswanathan, S. Pharmacokinetics and therapeutic efficiency of a novel cationic liposome
nano-formulated all trans retinoic acid in lung cancer mice model. J. Drug Deliv. Sci. Technol. 2017, 39,
223–236. [CrossRef]
99. Legut, M.; Lipka, D.; Filipczak, N.; Piwoni, A.; Kozubek, A.; Gubernator, J. Anacardic acid enhances the
anticancer activity of liposomal mitoxantrone towards melanoma cell lines—in vitro studies. Int. J. Nanomed.
2014, 9, 653–668.
100. Wang-Gillam, A.; Li, C.-P.; Bodoky, G.; Dean, A.; Shan, Y.S.; Jameson, G.; Macarulla, T.; Lee, K.H.;
Cunningham, D.; Blanc, J.F.; et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic
pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label,
phase 3 trial. Lancet 2016, 387, 545–557. [CrossRef]
Molecules 2018, 23, 907 17 of 17
101. Dawidczyk, C.M.; Kim, C.; Park, J.H.; Russell, L.M.; Lee, K.H.; Pomper, M.G.; Searson, P.C. State-of-the-art
in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
J. Control Release 2014, 187, 133–144. [CrossRef] [PubMed]
102. Dimopoulos, M.A.; Pouli, A.; Zervas, K.; Grigoraki, V.; Symeonidis, A.; Repoussis, P.; Mitsouli, C.;
Papanastasiou, C.; Margaritis, D.; Tokmaktsis, A.; et al. Prospective randomized comparison of vincristine,
doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal
doxorubicin as first-line treatment in multiple myeloma. Ann. Oncol. 2003, 14, 1039–1044. [CrossRef]
[PubMed]
103. Barenholz, Y. Doxil®–the first FDA-approved nano-drug: Lessons learned. J. Control Release. 2012, 160,
117–134. [CrossRef] [PubMed]
104. Ali, S.M.; Sheikh, S.; Ahmad, A.; Ahmad, M.U.; Chen, P.; Paithankar, M. Bioequivalence study of pegylated
doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL®in ovarian cancer patients: physicochemical
characterization and pre-clinical studies. J. Nanomed. Nanotechnol. 2016, 7, 361.
105. Gill, P.S.; Wernz, J.; Scadden, D.T.; Cohen, P.; Mukwaya, G.M.; von Roenn, J.H.; Jacobs, M.; Kempin, S.;
Silverberg, I.; Gonzales, G.; et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin,
bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 1996, 14, 2353–2364. [CrossRef]
[PubMed]
106. Fumagalli, L.; Zucchetti, M.; Parisi, I.; Viganò, M.G.; Zecca, B.; Careddu, A.; D’Incalci, M.; Lazzarin, A.
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with
HIV-associated Kaposi’s sarcoma. Cancer Chemother. Pharmacol. 2000, 45, 495–501. [CrossRef] [PubMed]
107. Tulpule, A.; Yung, R.C.; Wernz, J.; Espina, B.M.; Myers, A.; Scadden, D.T.; Cabriales, S.; Ilaw, M.; Boswell, W.;
Gill, P.S. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi’s
sarcoma. J. Clin. Oncol. 1998, 16, 3369–3374. [CrossRef] [PubMed]
108. Creutzig, U.; Zimmermann, M.; Bourquin, J.-P.; Dworzak, M.N.; Fleischhack, G.; Graf, N.; Klingebiel, T.;
Kremens, B.; Lehrnbecher, T.; von Neuhoff, C.; et al. Randomized trial comparing liposomal daunorubicin
with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004.
Blood 2013, 122, 37–43. [CrossRef] [PubMed]
109. Kucherov, F.A.; Egorova, K.S.; Posvyatenko, A.V.; Eremin, D.B.; Ananikov, V.P. Investigation of cytotoxic
activity of mitoxantrone at the individual cell level by using ionic-liquid-tag-enhanced mass spectrometry.
Anal. Chem. 2017, 89, 13374–13381. [CrossRef] [PubMed]
110. Ehninger, G.; Schuler, U.; Proksch, B.; Zeller, K.-P.; Blanz, J. Pharmacokinetics and metabolism of
mitoxantrone A Review. Clin. Pharmacokinet. 1990, 18, 365–380. [CrossRef] [PubMed]
111. Alderton, P.M.; Gross, J.; Green, M.D. Comparative study of doxorubicin, mitoxantrone, and epirubicin
in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992, 52,
194–201. [PubMed]
112. Xu, X.; Wang, L.; Xu, H.-Q.; Huang, X.-E.; Qian, Y.-D.; Xiang, J. Clinical comparison between paclitaxel
liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac. J.
Cancer Prev. 2013, 14, 2591–2594. [CrossRef] [PubMed]
113. Surapaneni, M.S.; Das, S.K.; Das, N.G. Designing paclitaxel drug delivery systems aimed at improved patient
outcomes: Current status and challenges. ISRN Pharmacol. 2012, 2012, 623139. [CrossRef] [PubMed]
114. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179–192.
[CrossRef]
115. Magin, R.L.; Hunter, J.M.; Niesman, M.R.; Bark, G.A. Effect of vesicle size on the clearance, distribution, and
tumor uptake of temperature-sensitive liposomes. Cancer Drug Deliv. 1986, 3, 223–237. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
